Biolife Solutions, Inc. (BLFS)

$24.04

+1.01

(+4.39%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $23.47
    $24.12
    $24.04
    downward going graph

    2.37%

    Downside

    Day's Volatility :2.69%

    Upside

    0.33%

    downward going graph
  • $8.92
    $24.04
    $24.04
    downward going graph

    62.9%

    Downside

    52 Weeks Volatility :62.9%

    Upside

    0.0%

    downward going graph

Returns

PeriodBiolife Solutions, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
31.37%
6.5%
0.0%
6 Months
31.75%
7.1%
0.0%
1 Year
18.47%
9.8%
0.0%
3 Years
-49.12%
14.2%
-20.2%

Highlights

Market Capitalization
1.0B
Book Value
$7.3
Earnings Per Share (EPS)
-1.42
PEG Ratio
65.38
Wall Street Target Price
25.44
Profit Margin
-45.84%
Operating Margin TTM
-31.18%
Return On Assets TTM
-8.04%
Return On Equity TTM
-18.2%
Revenue TTM
137.3M
Revenue Per Share TTM
3.1
Quarterly Revenue Growth YOY
-15.9%
Gross Profit TTM
54.1M
EBITDA
-43.1M
Diluted Eps TTM
-1.42
Quarterly Earnings Growth YOY
6.4
EPS Estimate Current Year
-0.57
EPS Estimate Next Year
-0.36
EPS Estimate Current Quarter
-0.28
EPS Estimate Next Quarter
-0.21

Analyst Recommendation

Buy
    86%Buy
    13%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Biolife Solutions, Inc.(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
12
12
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 5.82%

Current $24.04
Target $25.44

Company Financials

FY18Y/Y Change
Revenue
19.7M
↑ 79.11%
Net Income
3.3M
↓ 229.86%
Net Profit Margin
16.54%
↑ 39.36%
FY19Y/Y Change
Revenue
27.4M
↑ 38.64%
Net Income
11.1M
↑ 238.7%
Net Profit Margin
40.42%
↑ 23.88%
FY20Y/Y Change
Revenue
48.1M
↑ 75.69%
Net Income
2.7M
↓ 75.89%
Net Profit Margin
5.55%
↓ 34.87%
FY21Y/Y Change
Revenue
119.2M
↑ 147.79%
Net Income
-8.4M
↓ 414.32%
Net Profit Margin
-7.04%
↓ 12.59%
FY22Y/Y Change
Revenue
161.8M
↑ 35.75%
Net Income
-139.8M
↑ 1567.72%
Net Profit Margin
-86.43%
↓ 79.39%
FY23Y/Y Change
Revenue
143.3M
↓ 11.43%
Net Income
-66.4M
↓ 52.49%
Net Profit Margin
-46.36%
↑ 40.07%
Q4 FY22Q/Q Change
Revenue
44.3M
↑ 8.62%
Net Income
-49.2M
↑ 394.02%
Net Profit Margin
-111.14%
↓ 86.7%
Q1 FY23Q/Q Change
Revenue
37.7M
↓ 14.81%
Net Income
-13.7M
↓ 72.12%
Net Profit Margin
-36.37%
↑ 74.77%
Q2 FY23Q/Q Change
Revenue
39.5M
↑ 4.79%
Net Income
-10.2M
↓ 25.63%
Net Profit Margin
-25.82%
↑ 10.55%
Q3 FY23Q/Q Change
Revenue
33.3M
↓ 15.64%
Net Income
-29.1M
↑ 185.64%
Net Profit Margin
-87.41%
↓ 61.59%
Q4 FY23Q/Q Change
Revenue
32.7M
↓ 1.79%
Net Income
-13.4M
↓ 54.06%
Net Profit Margin
-40.89%
↑ 46.52%
Q1 FY24Q/Q Change
Revenue
31.7M
↓ 3.07%
Net Income
-10.2M
↓ 23.63%
Net Profit Margin
-32.22%
↑ 8.67%
FY18Y/Y Change
Total Assets
45.5M
↑ 274.43%
Total Liabilities
2.3M
↑ 13.07%
FY19Y/Y Change
Total Assets
93.0M
↑ 104.57%
Total Liabilities
10.0M
↑ 330.57%
FY20Y/Y Change
Total Assets
234.8M
↑ 152.47%
Total Liabilities
29.6M
↑ 196.27%
FY21Y/Y Change
Total Assets
552.6M
↑ 135.32%
Total Liabilities
71.9M
↑ 142.89%
FY22Y/Y Change
Total Assets
450.2M
↓ 18.53%
Total Liabilities
86.0M
↑ 19.75%
FY23Y/Y Change
Total Assets
412.7M
↓ 8.33%
Total Liabilities
75.1M
↓ 12.77%
Q4 FY22Q/Q Change
Total Assets
450.2M
↓ 7.68%
Total Liabilities
86.0M
↑ 8.32%
Q1 FY23Q/Q Change
Total Assets
446.5M
↓ 0.83%
Total Liabilities
88.4M
↑ 2.7%
Q2 FY23Q/Q Change
Total Assets
433.2M
↓ 2.98%
Total Liabilities
81.0M
↓ 8.28%
Q3 FY23Q/Q Change
Total Assets
411.2M
↓ 5.08%
Total Liabilities
79.1M
↓ 2.36%
Q4 FY23Q/Q Change
Total Assets
412.7M
↑ 0.38%
Total Liabilities
75.1M
↓ 5.16%
Q1 FY24Q/Q Change
Total Assets
401.6M
↓ 2.69%
Total Liabilities
68.2M
↓ 9.13%
FY18Y/Y Change
Operating Cash Flow
2.3M
↑ 288.1%
Investing Cash Flow
-6.5M
↑ 4421.2%
Financing Cash Flow
28.1M
↑ 486.86%
FY19Y/Y Change
Operating Cash Flow
1.2M
↓ 48.34%
Investing Cash Flow
-27.0M
↑ 315.66%
Financing Cash Flow
1.6M
↓ 94.33%
FY20Y/Y Change
Operating Cash Flow
6.5M
↑ 437.1%
Investing Cash Flow
-23.7M
↓ 12.17%
Financing Cash Flow
101.2M
↑ 6242.36%
FY21Y/Y Change
Operating Cash Flow
-4.8M
↓ 174.23%
Investing Cash Flow
-12.6M
↓ 46.73%
Financing Cash Flow
-2.8M
↓ 102.74%
FY22Y/Y Change
Operating Cash Flow
-8.5M
↑ 75.54%
Investing Cash Flow
-58.1M
↑ 359.71%
Financing Cash Flow
16.3M
↓ 687.37%
Q4 FY22Q/Q Change
Operating Cash Flow
7.9M
↑ 425.13%
Investing Cash Flow
-14.9M
↓ 6.23%
Financing Cash Flow
-624.0K
↓ 103.58%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.7M
↓ 134.52%
Investing Cash Flow
2.9M
↓ 119.65%
Financing Cash Flow
-562.0K
↓ 9.94%
Q2 FY23Q/Q Change
Operating Cash Flow
-7.7M
↑ 184.59%
Investing Cash Flow
9.3M
↑ 217.57%
Financing Cash Flow
704.0K
↓ 225.27%

Technicals Summary

Sell

Neutral

Buy

Biolife Solutions, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biolife Solutions, Inc.
Biolife Solutions, Inc.
7.17%
31.75%
18.47%
-49.12%
19.57%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
-1.32%
16.54%
32.6%
35.62%
148.32%
Resmed Inc.
Resmed Inc.
11.69%
9.57%
-6.0%
-19.79%
64.22%
Becton, Dickinson And Company
Becton, Dickinson And Company
0.5%
-1.64%
-17.69%
-6.68%
-8.49%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-14.37%
-23.3%
-26.95%
-26.58%
102.44%
Alcon Ag
Alcon Ag
2.41%
20.84%
8.21%
30.7%
54.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biolife Solutions, Inc.
Biolife Solutions, Inc.
NA
NA
65.38
-0.57
-0.18
-0.08
NA
7.3
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
78.14
78.14
7.13
6.63
0.16
0.08
NA
41.4
Resmed Inc.
Resmed Inc.
32.24
32.24
1.75
7.73
0.22
0.12
0.01
31.52
Becton, Dickinson And Company
Becton, Dickinson And Company
50.71
50.71
1.34
13.04
0.05
0.03
0.02
88.74
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
42.71
42.71
6.72
7.74
0.21
0.11
0.0
36.72
Alcon Ag
Alcon Ag
44.05
44.05
4.59
3.07
0.05
0.02
0.0
42.13
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biolife Solutions, Inc.
Biolife Solutions, Inc.
Buy
$1.0B
19.57%
NA
-45.84%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$161.3B
148.32%
78.14
27.65%
Resmed Inc.
Resmed Inc.
Buy
$30.8B
64.22%
32.24
20.91%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$68.6B
-8.49%
50.71
6.76%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$23.7B
102.44%
42.71
19.42%
Alcon Ag
Alcon Ag
Buy
$45.8B
54.72%
44.05
10.96%

Insights on Biolife Solutions, Inc.

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 39.50M → 31.72M (in $), with an average decrease of 6.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -29.13M → -10.22M (in $), with an average increase of 74.3% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 32.6% return, outperforming this stock by 14.1%

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 35.6% return, outperforming this stock by 84.7%

Institutional Holdings

  • Casdin Capital, LLC

    18.90%

  • BlackRock Inc

    11.86%

  • Vanguard Group Inc

    6.23%

  • Millennium Management LLC

    3.94%

  • William Blair Investment Management, LLC

    3.75%

  • Fred Alger Management, LLC

    3.23%

Company Information

bothell, wa-based biolife solutions, inc. (nasdaq: blfs), is a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers.

Organization
Biolife Solutions, Inc.
Employees
409
CEO
Mr. Roderick de Greef
Industry
Health Technology

Discover More

FAQs